Thus, using MDM2 inhibitor to restore the native tumor-suppressing functions of p53 and activate p53-dependent apoptosis in malignant cells has been considered a desirable treatment for cancer therapy (Saha et al., 2010). The gene discussed is TP53; the disease is cancer.